Clinical Trial Update: Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet [NA]

View source ↗

Summary

The trial evaluated the efficacy of ambrisentan in improving blood flow to the hands or feet in patients with limited cutaneous systemic sclerosis. Results were…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limited Cutaneous Systemic Sclerosis

Drugs mentioned

• LETAIRIS (ambrisentan)

Snippet

Sponsor: Soumya Chatterjee | Conditions: Ischemia | NA | Status: COMPLETED | Results posted: 2013-05-03